MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS’ December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company’s previously disclosed $100 million PIPE financing, and the advancement
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
